Parmax Pharma independent directors back ₹42.80-per-share open offer as fair, despite BSE close at ₹102.83
AI مارکیٹ کا خلاصہ
Parmax Pharma's independent directors committee endorsed the mandatory open offer at ₹42.80 as compliant with SEBI SAST pricing, but highlighted that the stock last traded far above the offer price, underscoring a wide market-to-offer spread. Separately, shareholders approved sizeable preferential equity and convertible warrant issuance to non-promoters, implying near-term capital structure changes and potential dilution dynamics. The development is idiosyncratic and limited in broader market impact.
اثر کی سطح
● لو
متاثرہ اثاثے
NCCOGOLD2USD/USDT+0.55%
AI تجزیاتی سمجھ · NCCOGOLD2USD/USDTAI تجزیاتی سمجھ
● Neutral
ابھی ٹریڈ کریں
⚠️ AI سے تیار کردہ تجزیاتی سمجھ خبروں کے مواد پر مبنی ہے اور صرف معلوماتی مقاصد کے لیے فراہم کی گئی ہے۔ یہ سرمایہ کاری کا مشورہ نہیں ہے اور نہ ہی BingX کے خیالات کی نمائندگی کرتی ہے۔ سرمایہ کاری میں رسک شامل ہے۔ براہ کرم ذمہ داری سے ٹریڈ کریں۔
Parmax Pharma’s committee of independent directors said on July 25, 2026 that the acquirers’ open offer price of ₹42.80 per share is fair and reasonable. The company’s shares, however, closed at ₹102.83 on BSE on July 24, 2026, well above the offer price. Separately, shareholders approved on July 2, 2026 a preferential allotment to non-promoter investors of 31,37,586 equity shares and 21,45,145 convertible warrants. The offer is a mandatory acquisition process tied to the company’s equity shares.
